Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor

BACKGROUND AND OBJECTIVE: Gilteritinib is a novel, highly selective tyrosine kinase inhibitor approved in the USA, Canada, Europe, Brazil, Korea, and Japan for the treatment of FLT3 mutation-positive acute myeloid leukemia. This article describes the clinical pharmacokinetic profile of gilteritinib....

Descripción completa

Detalles Bibliográficos
Autores principales: James, Angela Joubert, Smith, Catherine C., Litzow, Mark, Perl, Alexander E., Altman, Jessica K., Shepard, Dale, Kadokura, Takeshi, Souda, Kinya, Patton, Melanie, Lu, Zheng, Liu, Chaofeng, Moy, Selina, Levis, Mark J., Bahceci, Erkut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550323/
https://www.ncbi.nlm.nih.gov/pubmed/32304015
http://dx.doi.org/10.1007/s40262-020-00888-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550323/
https://www.ncbi.nlm.nih.gov/pubmed/32304015
http://dx.doi.org/10.1007/s40262-020-00888-w

Ejemplares similares